LON:INDV Indivior - INDV Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. GBX 1,961 +6.00 (+0.31%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range 1,915▼ 1,97350-Day Range 1,685▼ 2,015.3352-Week Range 1,052▼ 2,020Volume179,549 shsAverage Volume357,916 shsMarket Capitalization£2.68 billionP/E Ratio8,913.64Dividend YieldN/APrice TargetGBX 330 ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About Indivior (LON:INDV) StockIndivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comIndivior (LON:INDV) Reaches New 1-Year High at $1,999.00January 2, 2023 | finance.yahoo.comInvesting in Indivior (LON:INDV) three years ago would have delivered you a 861% gainJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 9, 2022 | finance.yahoo.comShould You Be Excited About Indivior PLC's (LON:INDV) 73% Return On Equity?December 7, 2022 | finance.yahoo.comIndivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth OutlookNovember 14, 2022 | finance.yahoo.comIndivior To Acquire Opiant PharmaceuticalsNovember 8, 2022 | finance.yahoo.comIndivior Third Quarter 2022 Earnings: EPS: US$0.29 (vs US$0.18 in 3Q 2021)October 27, 2022 | finance.yahoo.comIndivior Announces Q3 2022 Financial ResultsJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 11, 2022 | finance.yahoo.comIndivior PLC (LON:INDV) is favoured by institutional owners who hold 86% of the companySeptember 30, 2022 | finance.yahoo.comIndivior Shareholders Approve Resolutions to Proceed with Additional U.S. ListingSeptember 27, 2022 | businesswire.comAelis Farma: Availability of the 2022 Half-year Financial Report - Business WireSeptember 7, 2022 | finance.yahoo.comIndivior To Participate in Upcoming Investor Healthcare EventsAugust 30, 2022 | nasdaq.comIs EDAP TMS (EDAP) Outperforming Other Medical Stocks This Year? - NasdaqAugust 25, 2022 | finance.yahoo.comIndivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.August 15, 2022 | seekingalpha.comAddex, Indivior expand team up to develop therapies for substance use disorders - Seeking AlphaAugust 15, 2022 | globenewswire.comAddex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders - GlobeNewswireAugust 15, 2022 | finance.yahoo.comThese 4 Measures Indicate That Indivior (LON:INDV) Is Using Debt Reasonably WellAugust 12, 2022 | finance.yahoo.comAddex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022 - Yahoo FinanceAugust 9, 2022 | finance.yahoo.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Yahoo FinanceJuly 30, 2022 | morningstar.co.ukIndivior shares down amid drop in interim profit; eyes US listing - MorningstarJuly 28, 2022 | benzinga.comIndivior Announces H1 and Q2 2022 Financial Results - BenzingaJuly 28, 2022 | finance.yahoo.comIndivior Announces H1 and Q2 2022 Financial ResultsJuly 27, 2022 | finance.yahoo.comAddex Completes $4.2 Million Equity Financing - Yahoo FinanceJuly 26, 2022 | finance.yahoo.comCentessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - Yahoo FinanceJuly 25, 2022 | uk.finance.yahoo.comCentessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs - Yahoo Finance UKJuly 24, 2022 | finance.yahoo.comIndivior (LON:INDV) shareholders have earned a 80% CAGR over the last three yearsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address INDV Company Calendar Today1/31/2023Next Earnings (Estimated)2/14/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees885Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 330 High Stock Price ForecastGBX 330 Low Stock Price ForecastGBX 330 Forecasted Upside/Downside-83.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio8,913.64 Forward P/E Ratio1,850.00 P/E Growth-5.57Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio121.59 Current Ratio1.70 Quick Ratio1.52 Sales & Book Value Annual Sales£882 million Price / Sales3.03 Cash FlowGBX 731.69 per share Price / Cash Flow2.68 Book ValueGBX 164.80 per share Price / Book11.90Miscellaneous Outstanding Shares136,481,000Free FloatN/AMarket Cap£2.68 billion OptionableNot Optionable BetaN/A Key ExecutivesMr. Mark CrossleyCEO & Exec. DirectorMr. Ryan PreblickCFO & Exec. DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVP of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 51)Chief Legal Officer Mr. Jon FogleChief HR OfficerMr. Richard SimkinChief Commercial & Strategy OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMs. Nina DeLorenzoChief Global Impact OfficerMore ExecutivesKey CompetitorsUDG HealthcareLON:UDGAbcamLON:ABCDechra PharmaceuticalsLON:DPHBTGLON:BTGOxford Nanopore TechnologiesLON:ONTView All Competitors INDV Stock - Frequently Asked Questions Should I buy or sell Indivior stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INDV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INDV, but not buy additional shares or sell existing shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for Indivior's shares. Their INDV share price forecasts range from GBX 330 to GBX 330. On average, they anticipate the company's share price to reach GBX 330 in the next twelve months. This suggests that the stock has a possible downside of 83.2%. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2023? Indivior's stock was trading at GBX 1,852 at the beginning of the year. Since then, INDV shares have increased by 5.9% and is now trading at GBX 1,961. View the best growth stocks for 2023 here. When is Indivior's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023. View our INDV earnings forecast. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 1,961. How much money does Indivior make? Indivior (LON:INDV) has a market capitalization of £2.68 billion and generates £882 million in revenue each year. How many employees does Indivior have? The company employs 885 workers across the globe. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The official website for the company is indivior.com. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page (LON:INDV) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.